Company intelligence / Profile preview

Z-Alpha Therapeutics

San Diego, California, USAz-alpha.com ↗

Ownership: Private
Development stage: Other

Overview

Z-Alpha Therapeutics is an early-stage biopharmaceutical company focused on the development of next-generation targeted alpha radiotherapies. The company utilizes the alpha-emitting isotope Astatine-211 (211At), which offers advantages in safety, efficacy, and supply chain over traditional isotopes like Actinium-225. Their lead candidate, PMI21, is a PSMA-targeted radiotherapeutic for prostate cancer moving toward clinical trials.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalPeptide-drug conjugatePeptides
Industry: Biotech

Partnerships

D&D PharmatechZentera Therapeutics

Beyond the preview

Go deeper on Z-Alpha Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z-Alpha Therapeutics.